Ecology and neurobiology of toxin avoidance and the paradox of drug reward

Edward H. Hagen,1∗ Roger J. Sullivan2,3∗
Robert Schmidt,4,5 Genela Morris,5,6 Richard Kempter4,5
and Peter Hammerstein4

1Department of Anthropology
Washington State University, Vancouver, WA

2Department of Anthropology
California State University, Sacramento, CA

3Department of Psychiatry and Behavioral Sciences
UC Davis School of Medicine, Sacramento, CA

4Institute for Theoretical Biology
Humboldt-Universität zu Berlin, Germany

5Bernstein Center for Computational Neuroscience, Berlin, Germany

6Neuroscience Research Center of the Charité,
Universitätsmedizin Berlin, Germany

∗EH Hagen: hagen@vancouver.wsu.edu
∗RJ Sullivan: sullivar@csus.edu

October 24, 2008
Abstract. Current neurobiological theory of drug use is based on the observation that all addictive drugs induce changes in activity of dopaminergic circuitry, interfering with reward processing, and thus enhancing drug seeking and consumption behaviors. Current theory of drug origins, in contrast, views almost all major drugs of abuse, including nicotine, cocaine and opiates, as plant neurotoxins that evolved to punish and deter herbivores. According to this latter view, plants should not have evolved compounds that reward or reinforce plant consumption. Mammals, in turn, should not have evolved reinforcement mechanisms easily triggered by toxic substances. Situated in an ecological context, therefore, drug reward is a paradox. In an attempt to resolve the paradox, we review the neurobiology of aversive learning and toxin avoidance and their relationships to appetitive learning. We seek to answer the question: Why doesn’t aversive learning prevent the repeated use of plant drugs? We conclude by proposing alternative models of drug seeking and use. Specifically, we suggest that humans, like other animals, might have evolved to counter-exploit plant neurotoxins.

1 Introduction

Almost all major recreational drugs, including caffeine, nicotine, delta-9-tetrahydrocannabinol (THC, the active ingredient in cannabis), cocaine, amphetamines, and heroin (but excepting alcohol) are plant neurotoxins or, in the case of several synthetic drugs, their close chemical analogs. These drugs acquire their psychoactive effects by interfering with neuronal signaling in the central nervous system (CNS), for example by binding to neurotransmitter receptors, or interfering with neurotransmitter transport mechanisms (Wink, 2000). Many of the components of neuron signaling targeted by these toxins are ancient, and are found in most animals. For instance, the nicotinic acetylcholine receptor (nAChR), targeted by the neurotoxin nicotine, has an evolutionary history extending back about one billion years (Novere and Changeux, 1995). The nAChR mediates the CNS effects of nicotine by changing the levels of dopamine (DA), which is involved in reward processing. Crucial aspects of DA function, such as the dopaminergic neuromodulation of glutamatergic synapses, appear to be conserved across the eumetazoan clades (insects, vertebrates, mollusks, and nematodes) (Hills, 2006). The DA system is directly targeted by cocaine and, as we discuss later, is also heavily involved in the CNS effects of nicotine and other addictive drugs.

1Neurotoxins are defined by their ability to cause structural damage or functional disturbance of nervous tissues upon application of relatively small amounts.
Here we show that the two scientific traditions specializing in the physiological effects of plant neurotoxins are largely incompatible. The first tradition comprises phytobiologists, ecologists, and pharmacologists studying plants, plant-herbivore interactions, and plant secondary compounds. According to this tradition, many secondary compounds evolved to deter herbivores.

The second tradition focuses on the neurobiology of drug use and addiction in humans. This tradition emphasizes the important role of DA in reward-related behaviour and explains addiction as the result of drug interference with natural reward systems. According to neurobiologists, drugs such as nicotine, cocaine, opium, and THC activate neural circuits involved in reward processing, thus encouraging consumption. In seeming contradiction, plant biologists argue that such drugs evolved precisely because they successfully punished and deterred consumption. This apparent contradiction has been termed the *paradox of drug reward* (Sullivan and Hagen, 2002; Sullivan et al., 2008).

After describing the two perspectives in depth, we then take steps to address the paradox by reviewing the neurobiology of aversive learning and toxin avoidance and their relationships to appetitive learning. We seek an answer to the question: Why doesn’t aversive learning prevent the repeated use of those plant neurotoxins commonly used as drugs? We examine the possibility that drug exposure is an evolutionary novelty, and we propose alternative ‘ultimate’ models of drug seeking and use, according to which humans might have evolved to counter-exploit plant toxins in various ways.

2 Ecology: Punishment model of drug origins

There is a 300-400 million year history of antagonistic co-evolution between terrestrial plants, which photosynthesize chemical forms of energy for their own reproduction, and the bacterial, fungal, nematode, invertebrate and vertebrate herbivores that exploit plant tissues and energy stores for food and other nutrients, often severely damaging a plant’s ability to reproduce. To limit such damage, most plant species have evolved aggressive defense strategies to punish herbivores that feed on them. These strategies include mechanical defenses, such as thorns, as well as chemical defenses, such as toxins that interfere with herbivore growth, development, fecundity and other aspects of functioning (Karban and Baldwin, 1997).
2.1 Plant chemical defenses against herbivores

One broad category of chemical defenses includes compounds with relatively nonspecific effects on a wide range of molecular targets in the herbivore. Tannins and other phenolics, for instance, can form multiple hydrogen and ionic bonds with numerous proteins, changing their conformation and impairing their function (Wink, 2003).

Another broad category of defensive compounds interferes with specific aspects of herbivore physiology. Of central interest to us are those compounds that have evolved to interfere with signaling in the CNS and peripheral nervous system (PNS). Psychoactive plant-based drugs fall into this category. It is striking that different plant compounds interfere with nearly every step in neuronal signaling, including (1) neurotransmitter synthesis, storage, release, binding, and re-uptake (2) receptor activation and function; and (3) key enzymes involved in signal transduction (Wink, 2000). In many cases, plant compounds achieve these effects because they have evolved to resemble endogenous neurotransmitters. Many plant drugs are alkaloids – secondary metabolites containing nitrogen. Several alkaloids form a quaternary nitrogen configuration under physiological conditions, a structural motif present in most neurotransmitters (Wink, 2006).

The punishment model has successfully explained the function of many plant secondary metabolites (Swain, 1977; Wink, 1998). Even so, the precise evolved functions of most plant secondary compounds are still unknown, and among the popular plant drugs only nicotine, which we discuss next, has been conclusively shown to serve plant defense.

Nicotine

The defensive functions of nicotine are particularly well documented. We use nicotine examples throughout this article because, unlike other plant drugs, nicotine has been extensively studied from both ecological and neurobiological perspectives, and it is one of the world’s most popular plant drugs, behind only caffeine and chocolate. Furthermore, smoking is estimated to account for 12% of global adult mortality (Ezzati and Lopez, 2004), which makes tobacco consumption one of the scientific community’s most urgent, unsolved problems.

*Nicotiana attenuata*, a wild North American tobacco plant used by Native Americans, is an important model species for the analysis of plant-herbivore interactions involving nicotine. It is attacked by over 20 different herbivores, ranging from mammalian browsers to intracellular-feeding insects. These attacks induce defensive responses, including production of nicotine, which,
because it is costly for the plant, is allocated to tissues that are particularly important to plant fitness, and/or are likely to be eaten by herbivores (Baldwin, 2001). Studies in which nicotine production in *Nicotiana* is experimentally up- or down-regulated demonstrate the key role this neurotoxin plays in reducing leaf loss, reducing plant mortality, and increasing production of viable seed by deterring, harming and killing herbivores (Baldwin, 2001; Steppuhn et al., 2004).

Data on the ecological function of psychoactive compounds in most other plant drugs, such as THC, cocaine, morphine, codeine, and caffeine, are still emerging. However, studies to date also indicate defensive functions for these substances, such as herbivore feeding deterrence and microbe or animal toxicity (e.g., Nathanson et al., 1993; Wink et al., 1998; Hollingsworth et al., 2003; Rao et al., 2005). It is therefore likely that an ecological role similar to nicotine will be established for these psychoactive drugs too. Some plant compounds manipulate animals in ways other than punishment and deterrence. We will discuss those in section refaccident.

### 2.2 Co-evolved herbivore countermeasures

In response to the evolution of plant chemical defenses, herbivores have co-evolved a number of countermeasures (Karban and Agrawal, 2002; Petzinger and Geyer, 2006), including (1) compounds that prevent or attenuate induction of plant chemical defenses; (2) detoxification mechanisms, including enzymes and symbiotic relationships with microbes to detoxify or extract nutrients from plant defenses, and cellular membrane carrier proteins for toxin transport; and (3) chemosensors and aversive learning mechanisms that permit selective feeding on less toxic tissues. In sections 5 and 5.4, we explore aversion and aversive learning mechanisms in depth.

### 2.3 Multi-trophic interactions and pharmacophagy

Plant toxins, in addition to their direct effects on herbivores, often have pronounced effects on organisms directly or indirectly feeding on the herbivore (the third and higher trophic levels). This class of phenomena is termed tritrophic, or multitrophic, interactions (Price et al., 1980; Vet and Dicke, 1992; Ode, 2006). Nicotine is one of the toxins shown to impact multiple trophic levels (Thurston and Fox, 1972; Barbosa et al., 1986; Thorpe and Barbosa, 1986; El-Heneidy et al., 1988; Barbosa et al., 1991). Numerous invertebrates and vertebrates even actively sequester dietary toxins for their own chemical defense against predators (Daly et al., 2002; Laurent et al., 2005). This and other types of exploitation of plant secondary compounds is
termed *pharmacophagy* (Boppré, 1984). See figure 1. One study even found that the more toxin a plant produced, the more leaf area it lost to co-adapted beetle larvae exploiting the toxin for their own defense (Smiley et al., 1985). If exploitation of plant secondary compounds reduced plant fitness, as seems to be the case in this example, the plant would be expected to eventually evolve additional defenses. We will return to multi-trophic interactions and pharmacophagy in Section 6 because these might help resolve the paradox of drug reward.

### 2.4 Summary of the ecological perspective

In the story of life since the rise of complex terrestrial organisms more than 400 million years ago, one of the main plot lines has been the constant battle between plants, which dominate the biosphere, and diverse legions of herbivores. Plant secondary compounds have been potent, effective weapons to punish and deter herbivore enemies.

The foregoing ‘punishment’ model is an ultimate-level explanation of drug origins – it construes broad categories of plant compounds as defenses which arose during antagonistic co-evolution between plants and herbivores. Mayr (1961) introduced a distinction between such ultimate biological explanations, which invoke evolved responses to particular ecological conditions, and proximate biological explanations, which invoke physiological mechanisms (we will use the term ‘mechanism’ to refer to proximate mechanisms). The punishment model is at marked variance with the proximate, neurophysiological models usually employed by neurobiologists investigating human recreational drug use, to which we now turn.

### 3 Neurobiology: reward models of drug use

Neurobiological theory of drug use usually contrasts initial seeking and use with longer-term phenomena such as drug tolerance and addiction. Here we focus on initial drug seeking and use, deferring analysis of drug tolerance and addiction, for several reasons: There are a small number of simple and elegant information-processing models of initial drug seeking and use, often dubbed ‘reward models,’ that are well-supported by physiological evidence (briefly reviewed next). Current research on drug tolerance and addiction, in contrast, lacks a similarly concise, well-accepted conceptual framework (for a review of various theories of addiction, see West, 2001). Moreover, tolerance and addiction are generally attributed, in part, to complex changes in neurobiology induced by long-term drug exposure. It is difficult to evaluate
Figure 1: Possible example of pharmacophagy. Tobacco diet appears to protect tobacco hornworm (*Manduca sexta*), a tobacco specialist herbivore, from infection by a tomato-plant adapted sub-population of the parasitoid wasp *Cotesia congregata* (but not from a tobacco-plant adapted sub-population). A) Hornworm infected with 154 larva of the parasitoid wasp. B) Adult wasp emerging from cocoon. C) Early in the season, tomato-adapted parasitoids spent less time searching for hornworms on tobacco plants (more toxic) than tomato plants (less toxic). D) Fewer hornworms feeding on tobacco plants were infected by tomato-adapted parasitoids than hornworms feeding on tomato plants (tobacco-adapted parasitoids, in contrast, equally attacked hornworms feeding on tobacco or tomato plants). Charts redrawn from Kester and Barbosa (1994). Photographs ©Galveston County Master Gardener Association, Inc.
which changes are due to the corrosive effects of toxic drugs, however, and which to the nervous system’s attempt to adapt to drug exposure, hindering an evolutionary analysis.

3.1 ‘Reward’ and the activity of midbrain dopaminergic neurons

Food, safety, and (in sexually reproducing species) mating are essential for an organism to successfully contribute its genes to future generations. Evolutionary biologists refer to these as *fitness benefits*, and psychologists and neurobiologists as *rewards*. The behavioural definition of reward relates to stimuli that (1) reinforce behavior, or increase the frequency of behaviour that lead to the reward, (2) evoke approach or consummatory behaviour, and (3) produce hedonic reactions (Schultz, 2004).

There have been a number of recent, comprehensive reviews of the roles of the mesolimbic dopamine system (MDS) and reward-related learning in drug seeking and use (Everitt and Robbins, 2005; Kalivas and Volkow, 2005; Koob and Le Moal, 2005; Lüscher and Ungless, 2006; Nestler, 2005; Schultz, 2007). We therefore only briefly describe DA cell activity and influential models of the functional role of DA.

Dopamine neurons giving rise to the MDS play a central role in reward processing. These neurons are located in the midbrain structures of the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) and project to the nucleus accumbens (NAc) and dorsal striatum, comprised of the caudate and putamen. In a number of mammals, including rats and monkeys, electrophysiological recordings revealed transient increases in the activity of the VTA DA neurons when the organism encountered reward-related stimuli (Kelley and Berridge, 2002). The rise in activity of these dopaminergic projections increases the levels of extracellular DA in the NAc, mediating functional behavioral responses to reward-related stimuli (Koob and Le Moal, 2005; Nestler, 2005).

3.2 Addictive drugs modulate dopaminergic circuitry

Reward models of drug use are based on the observation that, despite their diverse effects on the CNS and PNS, all addictive drugs modulate DA activity in the MDS (Di Chiara and Imperato, 1988; Balfour, 2002; Fagen et al., 2003; Hyman et al., 2006; Nestler, 2005). Via disinhibition, excitation, or uptake blockade, each drug causes DA to increase in the NAc. The elevation in NAc DA levels affects normal reward processing mechanisms to enhance drug seeking and consumption.
Figure 2: Sites of action of nicotine in the MDS. Nicotinic receptors are located pre-synaptically on afferents to DA neurons. Their activation increases the amount of released neurotransmitter. On the post-synaptic site in the VTA they directly act on the DA neuron. In the target structures (NAc, striatum, frontal cortex) nicotinic receptors are mainly pre-synaptic, enhancing DA release. The natural ligand for these receptors is acetylcholine. In the VTA and SNc acetylcholine is secreted by projections from the brainstem pedunculopontine tegmental nucleus (PPTg), whereas in the NAc and striatum it is released by local interneurons.
Nicotine

To illustrate a few of the mechanisms by which an addictive drug elevates DA levels in the NAc, we focus on nicotine. Nicotine activates nAChRs, which are abundant in the CNS, PNS, as well as non-neuronal cells (Gotti and Clementi, 2004). We will concentrate on nAChRs located on (1) DA cells, (2) targets of the DA neurons (e.g., NAc, Fig. 1), and (3) inputs to the DA neurons. Nicotinic AChRs are ionic channels, which have direct impact on the neuron's membrane potential. Binding of nicotine to neuronal nAChRs causes depolarization. Those nAChRs located on the cell bodies of DA neurons immediately enhance excitation, and nAChRs on DA neuron nerve terminals increase release of DA in the target structures (Mansvelder et al., 2003; Rice and Cragg, 2004).

The duration of the nicotinic effect is determined by receptor desensitization, which depends, among other things, on the receptor subtype (Laviolette and van der Kooy, 2004). Although nicotine excites both excitatory and inhibitory inputs to the VTA DA neurons, differences in desensitization time courses of receptors cause a net increase in DA cell activity lasting for several minutes (Mansvelder et al., 2002). Furthermore, nicotine may also affect the fine temporal structure of DA signaling (Mameli-Engvall et al., 2006). Zhang and Sulzer (2004) elegantly demonstrated a differential desensitization of baseline vs. transient activity of DA neurons, effectively increasing prominence of the response (or enhancing the signal/noise ratio). On a longer time scale, the nicotine-induced increase in activity of the excitatory inputs leads to long-term potentiation (LTP) in this pathway (Mansvelder and McGhee, 2000).

The picture sketched here is unique to nicotine. Other drugs manipulate the MDS via different routes. We now describe the functional meaning of changes in DA neuron activity.

3.3 Functional roles of dopamine

There is widespread agreement about the importance of DA neurons to drug use, as well as for responses to beneficial stimuli, yet debate continues about their precise role in these behaviors. In an early interpretation of DA function in the MDS, dopaminergic systems were thought to directly mediate the rewarding or primary motivational characteristics of natural stimuli such as food, water, and sex, as well as the conditioned pleasure produced by stimuli previously associated with reward (e.g., Wise et al., 1978; Wise and Rompre, 1989), an hypothesis sometimes referred to as the hedonia hypothesis. Under this hypothesis, the DA increase caused by addictive drugs induces hedonic
Drug use, however, often does not produce hedonic or euphoric effects. Moreover, manipulation of DA transmission has a powerful impact on behaviour without changing hedonic reactions. It has therefore been argued that ‘wanting’ is distinct neurologically, psychologically, and conceptually from ‘liking,’ and that the MDS mediates wanting, not liking (i.e., not hedonia). In other words, DA assigns motivation to stimuli (Berridge, 2007), an hypothesis termed incentive-salience (Robinson and Berridge, 1993; Berridge and Robinson, 1998). Under this hypothesis, drug-induced DA release labels the drug as a ‘wanted’ stimulus.

Dopamine neurons fail to respond when animals receive an anticipated reward. This finding is in line with a computational reinforcement learning model (Montague et al., 1996; Schultz et al., 1997), suggesting that the response of midbrain dopaminergic neurons encode reward prediction errors, rather than absolute reward. Unpredicted rewards elicit activation of midbrain dopaminergic neurons (positive-prediction error), fully predicted rewards elicit no response, and the omission of predicted rewards induces a depression (negative-prediction error) (Montague et al., 1996; Schultz et al., 1997; Morris et al., 2004; Pan et al., 2005; Morris et al., 2006; Schultz, 2007). This reward prediction error signal is crucial for learning about reward-related stimuli. Under this hypothesis, the DA release following drug intake strongly reinforces the drug-taking behaviour.

In summary, despite debate on the exact role of DA, there is agreement that DA plays a major role in the processing of reward-related stimuli and that drug-induced DA release is central to drug use phenomena. All of these DA hypotheses therefore raise the paradox of drug reward.

4 Paradox of drug reward

To recapitulate our findings so far: Neurobiologists have developed a strong case that several plant neurotoxins stimulate reward and reinforcement circuitry in humans and other mammals. Theirs is a ‘proximate-level’ model, one grounded in physiological facts. Phytobiologists, on the other hand, have developed a strong case that many plant secondary metabolites, including psychoactive compounds, are best explained by their ability to punish, not reward, herbivores. From the ‘ultimate-level’, evolutionary biological perspective, it is therefore in the fitness interests of both plant and herbivore that the herbivore is averse to the plant’s defensive toxins. Specifically, plants should not have evolved defensive chemicals that easily trigger reward or reinforcement in consumers, and consumers should not have evolved neu-
ral mechanisms that readily reward or reinforce consumption of neurotoxins. Framed in the ultimate-level, evolutionary model of drug origins, drug reward is paradoxical (Sullivan et al., 2008).

Is drug reward an ‘accident’?

It is tempting to conclude, for several reasons, that drug reward might be an accident, and, if so, that this would resolve the paradox. First, it is unlikely that plant defensive chemicals evolved to deter herbivory by humans because a plant species’ defensive compounds should deter its principal herbivores, which could include various bacteria, fungi, nematodes, arthropods, and vertebrates. Plants also appear to have evolved compounds to inhibit the growth and reproduction of competing plants (caffeine, for instance, is an autotoxin, i.e., it is toxic to other coffee and tea plants; Singh et al., 1999). If plant drugs evolved primarily to deter non-mammalian herbivores (perhaps even a single specialist herbivore) or to inhibit the growth and reproduction of competing plants, their effects on mammals, and humans in particular, need not necessarily be toxic or aversive. Indeed, because the insect aversive system employs DA (see section 5), which underlies the reward system in mammals, a plant targeting dopaminergic systems in insects might inadvertently trigger reward or reinforcement in mammals. Second, a plant compound might have evolved to target one system in herbivores but accidentally activates other systems at the same time.

Third, if certain plant drugs evolved to perform strictly non-defensive functions then, for that drug, some (but not all) arguments for the paradox are lost. Indeed, it is known that a variety of plant compounds manipulate animals in ways other than punishment and deterrence. Many plants, for example, provide important benefits to animals, such as fruit and nectar, in order to obtain important services, such as pollen or seed dispersal. Tobacco and other plants emit scents that attract such pollinators and seed dispersers (Kessler et al., 2008). During and after attack by feeding insect larvae, many plants also increase emissions of volatile organic compounds, which attract predators of the larvae (Kessler and Baldwin, 2001). It is therefore at least conceivable that, to increase plant fitness, some plant drugs did not evolve to punish herbivores but instead to ‘manipulate’ animals, microbes, or even other plants, in unknown ways (see Section 5.5). It is also possible some drugs serve a purely internal function for the plant. To resolve the paradox for a particular drug, its precise ecological role will therefore have to be identified. (We hasten to add that although, conceivably, some drugs might not serve plant defense, the evidence supporting a defensive function for nicotine in tobacco is overwhelming, and it is a potent repellent to herbivores,
Finally, among the over 29,000 identified plant alkaloids (Wink, 2003) and other defensive compounds, humans might have simply discovered precisely those very few that, despite their toxicity to the target organisms, accidentally trigger human reward or reinforcement mechanisms (Nesse, 2002).

At present, we cannot assess the likelihood of an accidental activation of the midbrain DA system by some plant compounds. It is crucial to note, however, that the accident hypothesis (even if true) does not necessarily solve the paradox of drug reward. The (possibly) accidental elevation of NAc DA by plant compounds could provide a resolution of the paradox at the proximate level (i.e., one based on physiological rather than evolutionary considerations). Yet if the human nervous system and other elements of our physiology correctly identify drugs as toxins, an ultimate, evolutionary puzzle remains: why did we not evolve to avoid consuming recognizably toxic compounds, such as nicotine, despite any incidental rewarding or reinforcing effects?

Seeking an ultimate resolution of the paradox, we next briefly review the neurobiology of aversion and aversive learning, finding that drugs are recognized as toxins. We then discuss the interaction of appetitive and aversive learning in section 5.4. Finally, we propose and evaluate potential resolutions of the paradox in section 6.

5 Aversion and aversive learning

Consumption of poisonous compounds should invoke neurobiological processes involved with aversion and deterrence. Exposure to psychoactive drugs typically triggers two responses: Along with the drug-specific ‘rewarding’ or reinforcing effects, there is indeed an aversive reaction, as expected for toxins. Nicotine and cocaine, for example, can have both rewarding and aversive effects, including nausea, dizziness, headache and digestive malaise (Shoaib, 1998; Ettenberg, 2004; Risinger and Oakes, 1995; Eissenberg and Balster, 2000; Laviolette and van der Kooy, 2003a; DiFranza et al., 2004). Thus, physiologically, most drugs are correctly identified as toxic.

Encounter with aversive stimuli usually elicits a form of learning known as aversive learning, the ultimate goal of which is reduction in the behaviour that is associated with the aversive reaction. Aversive learning has been demonstrated in many species, from sea-slugs (Walters et al., 1981; 1979), nematodes (Nuttley et al., 2001), and insects (Vergoz et al., 2007; Unoki et al., 2006; 2005; Riemensperger et al., 2005; Glanzman, 2005; Schwaerzel et al., 2003) to rodents (Guimaraes et al., 1993; Nader et al., 2000; Wang
et al., 2005; Wilensky et al., 2006; Fanselow and Gale, 2003; Boatman and Kim, 2006; Lee and Kim, 2004; Davis, 1992; Maren and Quirk, 2004), rabbits (Frey et al., 1976), non-human primates (Paton et al., 2006), and humans (Seymour et al., 2007b; Delgado et al., 2006). Aversive learning is a core feature of behaviour.

5.1 Intake of highly toxic drugs is limited

Drug consumption is limited, probably by aversion and aversive learning. Typical quantities consumed by drug abusers are often worryingly close to the lethal dose. For 20 abused substances, Gable (2004) computed the ‘safety ratio,’ the ratio of the acute lethal dose to the dose most commonly used for non-medical purposes. Several plant drugs had surprisingly small safety ratios: heroin (intravenous) = 6, cocaine (intranasal) = 15, and codeine (oral) = 20. Although Gable did not examine nicotine, the lethal dose for an adult is estimated to be 30-60 mg (Gosselin et al., 1984). Because smokers typically absorb 0.5-2 mg per cigarette, and chewers up to 4.5 mg per “wad” (Hukkanen et al., 2005), the safety ratio for nicotine is roughly 20-40 (Room, 2006), on par with cocaine and codeine.

Worldwide, an estimated 15 billion cigarettes are smoked every day, and 1.3 billion adults, or 1/3 of the world’s adult population, are tobacco users (Guindon and Boisclair, 2003). Given these numbers, it is remarkable that there are almost no deaths from acute nicotine poisoning via smoking or chewing tobacco (Gable, 2004), although deaths from other types of nicotine poisoning are well known (e.g., from harvesting and processing tobacco, exposure to nicotine-based insecticides, or ingestion of cigarettes, cigars, or nicotine gum by children; de Landoni, 1991). Morbidity and mortality from chronic tobacco use, of course, is unquestionably high.

It seems, therefore, that humans have evolved a superbly efficient protective system against plant neurotoxins that helps to maintain a surprisingly low mortality rate. In neurobiological terms, the paradox of drug reward could therefore be rephrased: Why do aversion and aversive learning systems fail to prevent repeated consumption of certain plant neurotoxins?

5.2 Neurobiology of aversive learning

Despite many similarities between the underlying principles of appetitive (reward) and aversive associative learning, cumulative evidence seems to point to different, although converging, neuronal pathways signaling the different components of the association process. In mammals, a number of brain structures have been implicated with the signaling of aversive stimuli and with
aversive learning: the dorsolateral amygdala (Nitschke et al., 2006a; Fanselow and Gale, 2003; Maren, 2003; Nader et al., 2000; Zald and Pardo, 2002), anterior insula (Nitschke et al., 2006a), anterior cingulate cortex (Nitschke et al., 2006a; Johansen and Fields, 2004; Blair et al., 2006), and dorsolateral prefrontal cortex (Dunsmoor et al., 2008; Nitschke et al., 2006b). The dorsolateral amygdala, in particular, seems to be activated in response to unpleasant stimuli in a wide range of modalities, possibly mediating the Pavlovian response (Fendt and Fanselow, 1999; Seymour et al., 2007b).

The VTA, a component of reward processing as we discussed earlier, might also play a role in aversive learning. A VTA non-dopaminergic subpopulation is actually excited by aversive stimuli; furthermore, DA neurons in the VTA pause during aversive stimuli (Ungless et al., 2004). The DA pause during aversive stimuli could be an important signalling factor in aversive learning. It has also been proposed that DA signals aversive events via a non-phasic firing mode (Horvitz, 2000). Obviously, the precise role, or roles, of DA in the MDS, including reward, reinforcement, and aversion, bears strongly on understanding how a drug-induced increase in DA impacts drug use behavior.

Whereas there is a near-consensus on the role of midbrain DA in appetitive learning in mammals (Schultz, 2007; Ungless, 2004; but see also Berridge, 2007), the counterpart to this role in aversive learning has not yet been clearly identified. A theoretical study has implicated serotonin (Daw et al., 2002), but empirical evidence is lacking.

Insects’ reward and aversive systems, in contrast, have both been identified (Schroll et al., 2006; Giurfa, 2006). Interestingly, aversive learning in insects employs the dopaminergic system (Riemensperger et al., 2005; Vergoz et al., 2007), whereas appetitive learning is mediated by the octopaminergic system (Unoki et al., 2005). General features of insect aversive learning are similar to the mammalian DA reward learning system: the insect system has the ability to learn to predict future punishments and develops a response that is in accordance with a punishment prediction error (Riemensperger et al., 2005).

It therefore seems possible that neurotoxins targeting the insect aversive DA system could accidentally trigger the mammalian reward DA system. However, many plant drugs elevate DA in mammals via multiple signal cascades. A model in which these effects are transferred from the insect aversive system to the mammalian reward system would require important similarities in the neuroanatomical, pharmacological and physiological structure of the dopaminergic system in insects and mammals. There is currently little evidence for this. At least one study, for example, found the toxic effects of cocaine in insects to involve potentiation of octopamine neurotransmission.
not DA reuptake (Nathanson et al., 1993). Furthermore, in contrast to the idea that drugs will have opposite effects on insects and mammals, it has been argued that there are instead many similarities, e.g., an increase in locomotor activity for certain nicotine dosages (Wolf and Heberlein, 2003). Finally, although differences in neurotransmitter systems among herbivore species pose a problem to plants in developing general chemical defense mechanisms, there probably has been selection on most plants to produce toxins that successfully deter a range of invertebrate and vertebrate herbivores. Nicotine, for instance, is extremely toxic to both invertebrates and vertebrates (de Landoni, 1991).

5.3 Conditioned taste-aversion

Because we are interested in detection of, and responses to, dietary toxins by animals, we focus on results from an experimental paradigm based on oral consumption and taste.

Taste information is rapidly conveyed to the CNS through taste receptors located in the oral cavity. In the CNS, two neural pathways are activated by these inputs. Cortical gustatory regions code the quantitative and qualitative aspects of the tasted substance. In parallel, affective properties of the taste are processed in the insular cortex, amygdala and the VTA. These areas project to the feeding center in the lateral hypothalamus, thus controlling feeding behavior (Yamamoto, 2006).

Aversive learning following the consistent pairing of an artificially induced illness with oral consumption of a previously neutral, or even pleasant, substance is termed conditioned taste-aversion (CTA; Revusky and Bedarf, 1967; Revusky, 1968). Such aversive learning results in a decline in the consumption of the substance. It is important to note, however, that aversions are also readily formed to substances which the subject has tasted without ingesting, and in the absence of any consummatory response (Dickinson and Mackintosh, 1978).

CTA exhibits properties known from other forms of associative learning (for a review, see Klosterhalfen and Klosterhalfen, 1985). It is dependent on reliable presentations demonstrating the association of the conditioned stimulus (CS, taste) to the unconditioned stimulus (US, sickness) (McLaren and Dickinson, 1990), and is impeded by uncorrelated presentations of both, by repeated presentations of one stimulus and not the other, by non-causal presentations, and by total predictability of the US by other CS. Importantly, and similar to appetitive learning, CTA is sensitive to motivational modulation. Devaluation of the US, e.g., by habituation following aversive conditioning, reduces the magnitude of the avoidance response subsequently.
elicited by the CS (Rescorla, 1973).

Several features of CTA distinguish it from most forms of appetitive learning, however, highlighting the evolutionary importance of avoiding toxins. First, similar to other types of aversive learning, learning often occurs with a single pairing of CS and US (Barber et al., 1998). Second, conditioning can occur even when there are extremely long intervals between stimulus presentation and the sickness (McLaren and Dickinson, 1990). However, an inverse relation between the time delay and strength of learning still exists. Finally, animals seem disposed to readily associate illness or nausea with taste but not with other stimuli (Klosterhalfen and Klosterhalfen, 1985). Because most classes of psychoactive drugs can induce CTA (Cappell et al., 1973; Hunt and Amit, 1987), each of these features renders the failure to successfully acquire a distaste to drug consumption all the more puzzling. In summary, many psychoactive drugs seem to have the surprising property of being able to induce both aversive and rewarding effects (Hunt and Amit, 1987; Parker, 1995; Wise et al., 1976).

**Nicotine**

Nicotine is one of the psychoactive drugs that induces CTA. In rodents, for example, consumption of saccharin solution followed by subcutaneous injection of nicotine reduces future saccharin solution consumption (Korkosz et al., 2006; Castane et al., 2006). Direct injections of nicotine in the NAc can also produce CTA (Shoaib, 1998). In humans, nicotine injections induce aversive responses, especially in non-smokers (Eissenberg and Balster, 2000). The neural machinery that identifies nicotine as a toxin therefore exists and is functional.

### 5.4 Interaction of appetitive and aversive learning

In natural situations, appetitive and aversive learning mechanisms interact to achieve adaptive decision-making by comparing a behavior’s expected rewards (benefits) with expected punishments (costs). Therefore, an architecture must exist in which the two opposing motivational mechanisms, the aversive and appetitive ones, competitively interact and a decision is reached (Dickinson and Dearing, 1979; Seymour et al., 2007b). It has been long known, for instance, that pairing a CS with reward will suppress subsequent aversive learning to the same CS. Similarly, an appetitive CS will suppress aversive motivated behaviour (Pearce and Dickinson, 1975; Dickinson and Mackintosh, 1978).
In mammals, a number of (not necessarily mutually exclusive) brain structures have been proposed to serve as the site of an interaction between appetitive and aversive learning: different regions in the striatum (Seymour et al., 2007a), the amygdala (Balleine and Killcross, 2006; Paton et al., 2006), and the orbitofrontal cortex (Hosokawa et al., 2007). We suggest that the interaction of appetitive and aversion mechanisms, and their corresponding learning systems, are fundamental to the neurobiology of drug use, a point we illustrate with the complex interactions between the aversive and rewarding effects of nicotine.

**Nicotine**

Rewarding and aversive effects of nicotine administered to the VTA of rats were illustrated through place preference/avoidance paradigms (Laviolette et al., 2002; Laviolette and van der Kooy, 2003a;b). The value assigned to intra-VTA or systemic nicotine administration were dose dependent; high doses appeared to be rewarding whereas low doses caused aversion. Aversion was reversed to reward after blocking dopamine D2 receptors in the NAc. Note, however, that the D2 receptors, acting as autoreceptors on dopaminergic terminals in the NAc, downregulate DA release and upregulate DA reuptake (Wu et al., 2002). Thus it may be that the net effect of blocking these receptors resulted in an increase in the NAc DA level (Pucak and Grace, 1994).

Interaction of aversion and reward can also be mediated by different nAChR subtypes. In the NAc, they seem to differentially trigger aversion or reward in response to intra-VTA nicotine infusion. Specifically, the α7 subunit containing receptors are those that seem to mediate the rewarding effect of nicotine (Laviolette and van der Kooy, 2003b).

These and other findings indicate that besides reward and reinforcement effects, drugs of abuse exhibit aversive effects, and some interaction occurs in the VTA and NAc regions. From our ecological perspective, aversion and aversive learning, not reward and reinforcement, are the expected responses to neurotoxins. These results therefore suggest that an important next step in understanding the neurobiology of drug use will be to much more systematically investigate the interaction of appetitive and aversion mechanisms in response to drug exposure. In addition to reward-related and other effects, toxicity and aversion will probably be central components in future neurobiological models of initial acute drug exposure, a point made by others (e.g., Freeman et al., 2008; and references therein). Such proximate-level models cannot resolve the paradox because they do not explain why these systems
evolved to behave the way they do. Drug reward and reinforcement, in particular, remains a puzzle.

5.5 Aposematism: advertising toxicity

Neurobiological research on the effects of drugs on the CNS have focused on reward learning mechanisms, and to a lesser extent on aversive ones. However, other changes in the CNS due to drug consumption are well documented. Ecological concepts might shed light on some effects of drugs beyond reward and aversion.

Toxic animal species, like hornets, commonly evolve signals, such as distinctive coloring, to advertise their toxicity to predators, a phenomenon termed *aposematism* (Wallace, 1867; 1889; for some of the theoretical complexities, see Mallet and Joron, 1999; Mappes et al., 2005). These signals help predators to quickly and reliably learn to avoid these toxic prey. Although much less studied, aposematism in toxic plants also seems to have evolved, in the form of colors or odors (e.g., Harper, 1977; Eisner and Grant, 1981; Lev-Yadun and Gould, 2007).

We are interested in the possibility of selection on plants to send neurochemical aposematic signals to herbivores – an example of what ecologists variously refer to as *semiochemicals*, *infochemicals*, or *allelochemicals* (Law and Regnier, 1971; Nordlund and Lewis, 1976; Dicke and Sabelis, 1988) – and selection of herbivores to evolve neural machinery to detect such signals.

Cocaine, for example, alters the content of brain serotonin and norepinephrine (Filip et al., 2005; Hall et al., 2004; Hnasko et al., 2007). ACh levels are also altered following cocaine use (Fink-Jensen et al., 2003), and it is likely that cholinergic neurons participate in the rewarding effects of other drugs of abuse (Smith et al., 2004). Much effort has been devoted to study the eventual funneling of these effects to modulation of NAc dopamine levels (for review, see Lüscher and Ungless, 2006). Because alterations in brain NE, serotonin and ACh levels are associated with differences in arousal levels, memory and attention (Dani, 2001; Arnsten and Li, 2005; Corbetta et al., 2008; Everitt and Robbins, 1997; Reuter et al., 2007; Sarnyai et al., 2000), they might be facets of plant-herbivore signaling.

To signal toxicity, we suggest that plants could have evolved compounds to manipulate elements of herbivore nervous systems by passing through the blood-brain barrier to directly trigger attention, aversion, and other learning mechanisms in the CNS. Aspects of plant chemical cocktails could be the neurochemical equivalents of the hornet’s distinctive black and yellow bands. Moreover, the triggering of aversion and aversive learning after neurotoxin administration might not only be a physiological reaction to the toxic elements
of the plant, but could also be directly stimulated by plants to advertise their toxicity.

Even if this speculation were true, it would not resolve the paradox of drug reward. But such aposematic signaling could illuminate the interaction between certain plant neurotoxins and various systems in the PNS and CNS other than reward and reinforcement, e.g., those systems involved with attention to, and learning about, features of the local environment, especially dangerous features. See section 6.2.3 for a brief discussion of cognitive benefits of some plant drugs.

6 Towards resolving the paradox

We now explore three avenues towards resolving the paradox of drug reward: evolutionary novelty, non-defensive functions of secondary compounds, and counter-exploitation.

6.1 Is drug exposure an evolutionary novelty?

Nesse and Berridge (1997) proposed that current patterns of drug exposure are an evolutionary novelty, and therefore drugs, at least in their pure form, were probably not a selection pressure on human neurophysiology. If true, our brains might not be adapted to recognize psychoactive drugs as toxic, and reward circuits might inadvertently be triggered when such drugs are consumed.

Although particular drugs are probably evolutionarily novel (e.g., nicotine from the New World tobacco plant), we note that psychoactive drug use (1) primarily involves plant toxins, compounds that have been an important part of animal diets for hundreds of millions of years; (2) does trigger toxin avoidance mechanisms in most individuals, including aversive reactions to evolutionarily novel compounds such as nicotine, even in pure form; (3) is a pan-human phenomenon, involving similar substances and concentrations across a diverse array of cultures; and (4) is widespread in the archaeological record, at least for much of the Holocene (Sullivan and Hagen, 2002; Sullivan et al., 2008). Moreover, humans, like other animals, have evolved several layers of protection against plant toxins, including receptors for detecting, and enzymes for metabolizing, plant neurotoxins and other xenobiotics. Evidence of conserved function, stabilizing selection, and population-specific selection of at least some human bitter taste receptors (Soranzo et al., 2005, but see Wang et al., 2004) and xenobiotic metabolizing cytochrome P450 genes indicates a long evolutionary exposure to plant toxins as a class, albeit at reduced
levels relative to other primates (Sullivan et al., 2008). Aversion and aversive learning (reviewed in section 5) and the blood brain barrier, which provide protection mechanisms against many plant toxins, are additional evidence that mammalian evolution has been shaped by exposure to plant defensive compounds.

Nesse and Berridge (1997) also argued that novel routes of drug administration bypass adaptive information processing systems to act directly on mechanisms controlling emotion and behavior. This might be true for some drugs (e.g. injecting heroin), but for others (e.g. chewing coca or tobacco leaves) it is not. Even so, injection of pure drugs can still cause aversive reactions in most individuals (for such data on subcutaneous injections of pure nicotine in humans, see Foulds et al., 1997).

Tobacco, marijuana, areca palm, opium poppy, coca, coffee, tea, and cacao are domesticates. This means that in the last several thousand years their profile of secondary compounds has likely been tailored by artificial selection to fit human preferences. Hence, the precise recipes of these drug cocktails are evolutionarily novel. Nevertheless, at least when it comes to nicotine, the level of drug in commercially marketed products is similar to that in the tobacco and other nicotine-containing plants (wild and domestic) long used by indigenous peoples (Sullivan and Hagen, 2002). Domestication also implies significant interaction between humans and the wild progenitor species, presumably to obtain access to the same psychoactive substances. We therefore conclude that, despite these complications, exposure to potent psychoactive plant toxins as a class is probably not an evolutionary novelty for humans.

6.2 Counter-exploitation of plant neurotoxins

As an alternative to the preceding hypotheses, we propose that attraction to toxic plant compounds might have actively evolved because of benefits accruing from their consumption. We have argued for the existence of superbly well-functioning neurobiological mechanisms for toxin defense, and that interactions between appetite and aversion clearly play a central role in drug use patterns. In light of this conclusion, the inability of the latter defense mechanisms to completely prevent any use of tobacco, cocaine, opiates, and other psychoactive drugs raises the possibility that during the evolution of the human lineage there were biological fitness benefits associated with regulated consumption of these substances.
6.2.1 Costly signaling

Diamond (1992) proposed that drug use could be a costly signal, or handicap (Spence, 1973; Zahavi, 1975), one solution to the paradoxical propensity of humans to consume toxins. Just as the large, bright tail of the male peacock is a signal to females that the male is probably fit and healthy – because only then could he afford such a costly ornament – consuming a potent neurotoxin with few ill effects could also signal health and fitness to potential mates (see also Hill and Chow, 2002). We think drug use as a costly signal is an intriguing avenue to explore, and hope to see this hypothesis developed further. One challenge for future theorizing is that the costly signaling hypothesis requires individuals to minimize negative effects on overall system functioning after consuming neurotoxins, yet the aim of many drug users is to distort perception (i.e., to increase rather than minimize costs). Perhaps the fitness signal is a function of dose vs. effect, or even includes the ability to fully recover from, rather than simply minimize, the consequences of toxin consumption. Finally, many users consume drugs to enhance cognitive performance (Sahakian and Morein-Zamir, 2007), which is a benefit rather than a cost.

6.2.2 Pharmacophagy: Exploiting plant ‘research and development’ against parasites

Terrestrial plants account for about 50% of net primary production, and represent over 99% of primary producer biomass (Field et al., 1998). Excluding a large class of decomposers (organisms that consume dead plant and animal tissue), a substantial fraction of the world’s viruses, bacteria, fungi, nematodes and arthropods feed off living plants. Hence, an enormous quantity of pharmaceutical ‘research and development’ against these parasites has been, and continues to be, conducted by naturally evolving plant species. The same major categories of parasites also attack humans and other animals. It has been demonstrated, for example, that bacterial pathogens of plants and animals employ similar infectious strategies (e.g., Type III secretion systems), which has selected for convergent defenses in plants and animals (Schultz, 2002).

Animals counter-exploit plant toxins against parasites. To inhibit and kill their own parasites, some animals might have evolved to counter-exploit the products of hundreds of millions of years of ‘research’ by plants. As we noted earlier, there is evidence that a number of herbivores evolved to subsist on a mixed diet of palatable and toxic plants, in effect trading off
diet quality (and thus growth) for what is termed enemy-reduced or enemy-free space (e.g., Singer and Stireman, 2003). Even more intriguing is evidence that some herbivores contingently vary the toxicity of their diet in response to infection. In one study, for example, unparasitized caterpillars (Platyprepia virginalis) were more likely to survive on a diet of lupin (low toxicity), whereas caterpillars parasitized by a tachnid parasitoid (Thelaira americana) were more likely to survive on poison hemlock. When offered a choice of both plants in field tests, parasitized caterpillars were more likely to choose hemlock, and unparasitized caterpillars were more likely to choose lupin (Karan and English-Loeb, 1997). For a recent review of this field, see Ode (2006).

Primates, too, appear to engage in pharmacophagy (Johns, 1990; Huffman, 1997; 2007). In humans, it has been proposed that toxins in fava beans and cassava might be effective against Plasmodium falciparum infections, explaining geographic use patterns of these plants and genetic polymorphisms (Jackson, 1990; 1996); and the ubiquitous use of spices could be an adaptation to exploit plant toxins to combat bacterial infections of food (Billing and Sherman, 1998). Sullivan and Hagen (2002) hypothesized that hominins may have exploited plant toxins to overcome nutritional and energetic constraints on CNS signaling.

**Nicotine and other popular plant drugs fight parasites.** Intriguingly, some recreational drugs are remarkably effective treatments for mammalian pathogens. For example, nicotine, arecoline (the principle psychoactive component of betelnut, widely chewed in Asia and the Pacific), and THC, three of the world’s most popular plant drugs (along with chocolate and caffeine), are potent anthelmintics. Nicotine, arecoline, and their close chemical relatives have been widely used to de-worm livestock (Hammond et al., 1997; World Health Organization, 1981; Iqbal et al., 2006; Msolla et al., 1987; Kabelik et al., 1960; Kohler, 2001; Tomizawa and Casida, 2005); cannabis is toxic to plant-parasitic nematodes (Grewal, 1989; McPartland, 1997; McPartland and Glass, 2001). These compounds are also frequently mentioned as anthelmintics in the ethnomedical literature (e.g., Fabricant and Farnsworth, 2001; McPartland and Glass, 2001).

Thus, speculatively, the widespread recreational use of tobacco, betelnut, and cannabis could be a form of human pharmacophagy, an evolved response to chronic infections of helminths, or other parasites with nicotinic or muscarinic receptors, in ancestral human populations (the source of the nematocidal effects of cannabis are currently unknown; McPartland and Glass, 2001). We doubt, however, there was selection for use of these plant...
drug specifically; instead, there could have been selection to seek out and use plants rich in cholinergic agents (there are a number of cholinergic plant toxins; Wink and Schimmer, 1999) and other toxins of various types.

6.2.3 Other potential benefits

Neurotoxins have other effects that may be beneficial under certain conditions: cannabis and opiates are powerful analgesics; caffeine and nicotine can act as cognitive enhancers (Basbaum and Fields, 1978; Chaperon and Thiebot, 1999; Ignelzi and Atkinson, 1980; Lieberman, 2003; Rezvani and Levin, 2001). These effects are related to the fact that plant drugs chemically mimic endogenous signaling molecules.

The question is, if it is possible to enhance performance by ingesting compounds that chemically resemble endogenous signaling molecules, why didn’t natural selection simply increase production of the endogenous signaling molecules? There are a variety of potential answers involving evolutionary constraints, tradeoffs, and the like. Sullivan and Hagen (2002) suggested that although levels of endogenous signaling molecules are probably close to optimal in healthy individuals under normal circumstances, internal signaling functions would occasionally become compromised, perhaps due to deficiencies in dietary precursors in marginal environments, excess utilization of signaling molecules (e.g., as a consequence of chronic high stress), or disease. In such cases, limited doses of some plant secondary compounds might have been able to partially compensate for impaired functionality. It is also possible, in humans at least, that cultural evolution or even rational thought could identify benefits from plant compounds that offset the costs of exposure. This is obviously the case in modern medicine, which often exploits plant-derived compounds for clinical applications: one third of the current top 20 drugs on the market are plant derived (Howitz and Sinclair, 2008).

Cholinergic brain systems play important roles in attention and memory, for example, and also have been implicated in Alzheimer’s disease, schizophrenia and other mental illnesses. Nicotine and other nicotinic agonists correspondingly improve performance on attention and memory tasks, and clinical studies have shown nicotine to be an effective treatment for some of the cognitive deficits associated with the aforementioned diseases (Rezvani and Levin, 2001).

Thus, in principle, drug-seeking behaviour, and its neurophysiological basis, could have evolved because of beneficial effects of neurotoxins. We do not doubt that these neurotoxins constitute serious health hazards. Rather, these health hazards, which often appear only at high doses or later in life,
may have been offset by immediate benefits, resulting in a net increase in biological fitness.

### 6.2.4 Counter-exploitation mediated by the MDS?

Drug effects on the CNS are currently interpreted in terms of two general, and largely distinct, proximate mechanisms: one related to reward, centered on the MDS, and the other to aversion (reviewed in sections 3 and 5). These systems, however, do interact (reviewed in section 5.4). One hypothesis is that if humans and other mammals did evolve to counter-exploit plant neurotoxins, then the interaction of appetitive and aversive mechanisms effectively regulates exposure to neurotoxins. According to this conjecture, the benefits of exposure lead to the evolution of mechanisms in which useful neurotoxins activate reward and reinforcement to counterbalance pre-existing aversion and aversive learning mechanisms. This predicts, for example, that for any animal which has evolved to counter-exploit a plant toxin, reward and reinforcement mechanisms in that animal will activate when the animal is exposed to the counter-exploited toxin. Conversely, unexploited toxins will not activate reward and reinforcement mechanisms.

Because plants have a well-demonstrated ability to subvert herbivore nervous systems, a fully developed toxin counter-exploitation model would also have to consider that co-evolving plants, to deter consumption, will attempt to subvert reward, reinforcement and aversion mechanisms.

### 7 Concluding remarks

We see no easy resolution to the paradox that plant drugs – compounds which probably evolved to defend plants from herbivores – reinforce their own consumption in laboratory animals and humans. An ecological perspective, however, indicates some future directions for neurobiological research on drug use. First, exposure to potent psychoactive substances is unlikely to be an evolutionary novelty, but more data on the domestication of drug plants could yield important insights into this issue. Second, drugs should, and do, trigger aversion and aversive learning circuitry. Examining the relationship between drugs and signaling pathways downstream from chemoreceptors could therefore yield interesting results. More generally, aversion and aversive learning, and their interactions with reward and reinforcement, are likely to play central roles in proximate neurobiological models of drug use. A pure reward and reinforcement model of initial acute drug exposure is therefore problematic. Third, plant drugs could be components of plant-
animal signaling. This means that in addition to their toxic effects, plant chemical cocktails might have evolved to trigger PNS and CNS systems in herbivores involved with attention to, and learning about, the local environment. Fourth, because some drugs are so toxic, the relative absence of overdoses suggests the mechanisms mediating drug use are regulatory. The challenge, then, is to understand why the human brain appears to be regulating, rather than eliminating, exposure to certain neurotoxins. We speculate that consumption of some drugs might once have provided a benefit that offset the costs, perhaps as costly signals of fitness, protection against parasites, or a means to adaptively modulate endogenous signaling systems. If so, only such counter-exploited neurotoxins or their close chemical analogs should reinforce their own use.
Abbreviations

CNS, central nervous system; CS, conditioned stimulus; CTA, conditioned taste-aversion; DA, dopamine; LTP, long-term potentiation; MDS, mesocorticolimbic dopamine system; NAc, nucleus accumbens; nAChR, nicotinic acetylcholine receptor; PNS, peripheral nervous system; US, unconditioned stimulus; THC, delta-9-tetrahydrocannabinol; VTA, ventral tegmental area;

Acknowledgements

We thank Hagai Bergman, Dori Derdikman, Brian Hyland, Olof Leimar, Jonas Rose, Inbar Saraf-Sinik and Kay Thurley for discussions and valuable comments on the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft (Emmy-Noether grant ‘Ke 788/1-4’ to RK; SFB 618 ‘Theoretical Biology’ to PH and RK) and the BMBF (Bernstein Center for Computational Neuroscience Berlin, grant ‘01GQ0410’ to RK). EHH and RJS are co-first authors; RK and PH are co-last authors.
References


Comparative Study.


